Baxter touts cost savings of Floseal in economic analysis studies

Baxter (NYSE:BAX) this week touted the publication of 2 health economic analyses of its Floseal hemostatic matrix, touting it as a cost-saving solution for hospitals to control bleeding during cardiac and spinal surgeries.

Data in the studies came from previously published retrospective studies of a large US hospital billing database, according to Baxter. Results were published recently in the Journal of Medical Economics.

In an analysis of cardiac surgery procedures, researchers reported a potential cost savings of $1.5 million when using Floseal when compared to Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon’s Surgiflo, assuming improved clinical outcomes similar to those in a prior retrospective study.

In a 2nd study of spinal surgeries, researchers reported a potential cost savings of $151 per major and $574 per severe spinal surgery when comparing the use of Floseal to Surgiflo.

Researchers also reported a possible improvement in average surgical volume, improved surgical outcomes and efficiencies as a result of shorter operative room time, lower blood transfusion rate and lower product volume use.

“Based on the real-world outcomes observed in the earlier study, this new health economics analysis identifies a substantial opportunity for hospitals to realize potential cost savings on cardiac surgery operations, which are among the surgical specialties the most susceptible to the occurrence of intra-operative and post-operative bleeding,” study co-author Dr. Domenico Calcaterra of Minnesota’s Abbott Northwestern Hospital said in a press release.

The post Baxter touts cost savings of Floseal in economic analysis studies appeared first on MassDevice.

from MassDevice http://ift.tt/2mKtV0l